MAPT and Alzheimer disease: Although brain insulin resistance influences amyloid and tau pathology (Guerrero-Berroa et al., 2014; Berlanga-Acosta et al., 2020; Kellar and Craft, 2020), the cerebral burden of AD-related pathology is not increased in individuals with T2D compared to non-diabetic (Beeri et al., 2005; Arvanitakis et al., 2006; Abner et al., 2016; Dos Santos Matioli et al., 2017; Biessels et al., 2020; Kellar and Craft, 2020).